| Date | Title | Description |
| 26.03.2026 | AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress | AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress
Thu, Mar 26, 2026 08:00 CET Report this content
STOCKHOLM, Sweden – March 26, 2026 – AnaCardio today announces that ... |
| 11.03.2026 | AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s | AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s
Wed, Mar 11, 2026 09:00 CET Report this content
Stockholm, Sweden and Lugano, Switzerland, March 11, 2026 - AnaCardio, a clinical-stage biopharmac... |
| 10.12.2025 | AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b | AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b
Wed, Dec 10, 2025 08:00 CET Report this content
December 10, 2... |
| 29.09.2025 | Scaling lessons for tech companies: Quotes from successful European deep tech founders | If you think attracting investment is tough for a regular startup, imagine for a moment what it’s like for a deep tech founder.
You’ve developed a groundbreaking technology, often the result of years of R&D and lab work. Now you’re thru... |
| 16.09.2025 | AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025 | AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025
Tue, Sep 16, 2025 09:00 CET Report this content
Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-sta... |
| 02.09.2025 | AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer | AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer
Tue, Sep 02, 2025 09:00 CET Report this content
Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutica... |
| 17.07.2025 | AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF | AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF
Thu, Jul 17, 2025 09:00 CET Report this content
Alignment reached with both the FDA and EMA ... |
| 13.03.2025 | AnaCardio receives patent grant in Europe for AC01 | AnaCardio receives patent grant in Europe for AC01
Thu, Mar 13, 2025 09:00 CET Report this content
Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractil... |
| 25.02.2025 | AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF) | AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)
Tue, Feb 25, 2025 09:00 CET Report this content
February 25, 2025, Stockholm, Sweden - AnaCardi... |
| 11.01.2025 | AnaCardio's €19 Million Leap: A New Dawn for Heart Failure Treatment | In the world of biopharmaceuticals, every funding round can feel like a heartbeat—vital and pulsating with potential. AnaCardio, a clinical-stage startup based in Stockholm, has just secured €19 million (approximately USD 19 million) to adv... |
| 10.01.2025 | AnaCardio pumps €19 million into heart failure treatment innovation | AnaCardio, a clinical-stage biopharmaceutical startup headquartered in Stockholm, has secured €17.8 million in a Series A extension round to develop their drug candidate AC01.
The financing was co-led by Novo Holdings, Pureos Bioventures, a... |
| 09.01.2025 | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure
Thu, Jan 09, 2025 09:00 CET Report this content
Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ... |
| 19.09.2024 | Promising Advances in Cancer and Heart Failure Treatments: A Look at Harbour BioMed and AnaCardio | In the world of biopharmaceuticals, innovation is the lifeblood. Two companies, Harbour BioMed and AnaCardio, are making waves with their latest clinical trials. Both are pushing the boundaries of treatment for serious health conditions: ad... |
| 17.09.2024 | AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update | AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update
Tue, Sep 17, 2024 08:30 CET Report this content
PRESS RELEASE
Stockholm, Sweden, September 17, 2024
AnaCardio, a Swedish clinical-stage biopharma... |
| 21.08.2024 | Shifting Gears in Biotech: SciBase and AAX Biotech Make Strategic Moves | In the fast-paced world of biotechnology, change is the only constant. Companies must adapt, evolve, and sometimes pivot to stay relevant. Recently, two Swedish biotech firms, SciBase and AAX Biotech, made significant announcements that ref... |
| 21.08.2024 | AAX Biotech appoints Patrik Strömberg to Board of Directors, enhancing leadership team | AAX Biotech appoints Patrik Strömberg to Board of Directors, enhancing leadership team
Wed, Aug 21, 2024 07:30 CET Report this content
AAX Biotech is pleased to welcome Patrik Strömberg as new board member. Patrik Strömberg brings over two ... |
| 03.06.2024 | Michael Grissinger appointed as new Chairman of AnaCardio | Michael Grissinger appointed as new Chairman of AnaCardio
Mon, Jun 03, 2024 08:00 CET Report this content
PRESS RELEASE
Stockholm, Sweden, June 3, 2024
AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing nov... |
| 04.04.2024 | AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation Summit | AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation Summit
Thu, Apr 04, 2024 18:00 CET Report this content
PRESS RELEASE
Stockholm, Sweden, April 4 , 2024
AnaCardio, a Swedish clinical-stage biopharm... |
| 17.01.2024 | AnaCardio receives second tranche of SEK 50 million, completing the previously announced Series A round | AnaCardio receives second tranche of SEK 50 million, completing the previously announced Series A round
Wed, Jan 17, 2024 12:00 CET Report this content
PRESS RELEASE
Stockholm, Sweden, January 17, 2024
AnaCardio, a Swedish clinical-stage bi... |
| 17.01.2024 | Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round | - |
| 17.08.2023 | AnaCardio receives IND approval from the FDA for AC01 to Start a Clinical Pharmacology Study | AnaCardio receives IND approval from the FDA for AC01 to Start a Clinical Pharmacology Study
Thu, Aug 17, 2023 08:00 CET Report this content
PRESS RELEASE
Stockholm, Sweden, August 17, 2023
AnaCardio, a Swedish clinical-stage biopharmaceuti... |
| 13.04.2023 | AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK | AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK
Thu, Apr 13, 2023 12:00 CET Report this content
Solna, Sweden and Lugano, Switzerland, April 13, 2022 - An... |
| 14.03.2023 | Ghrelin treatment in heart failure patients showed increased contractility of the heart | Ghrelin treatment in heart failure patients showed increased contractility of the heart
Tue, Mar 14, 2023 13:22 CET Report this content
AnaCardio´s founder Prof Lars Lund and colleagues from The Karolinska Institutet publish study on ghreli... |
| 17.11.2022 | AnaCardio Receives Regulatory Approval to Start a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK | AnaCardio Receives Regulatory Approval to Start a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK
Thu, Nov 17, 2022 09:13 CET Report this content
STOCKHOLM, SWEDEN - 17 November 2022: AnaCardio today announces approva... |
| 09.09.2022 | AnaCardio Raises Approx. USD14.21M in Series A Funding | AnaCardio, a Swedish clinical-stage biopharmaceutical company, completed a Series A funding round of SEK 150m (approx. USD14.21m).
The financing round was led by Flerie Invest with Industrifonden as co-leader. 3B Health Ventures participate... |
| 07.09.2022 | AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failure | AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failure
Wed, Sep 07, 2022 08:00 CET Report this content
STOCKHOLM, SWEDEN - 7 September 2022: AnaCardio announced today the completion of a SEK 150 M Series A financin... |
| 07.09.2022 | Karolinska Development’s portfolio company AnaCardio raises SEK 150 million to start clinical trial with candidate drug AC01 in heart failure | STOCKHOLM, SWEDEN September 7, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed a series A investment round of SEK 150 million from a group of long-term and reputabl... |
| 07.09.2022 | AnaCardio raises 150 million SEK in series A round co-led by Industrifonden | Today we are happy to announce our investment in AnaCardio and are excited to support their important mission of developing a drug that has the potential to dramatically improve the lives of people suffering from heart failure. The 150 mill... |
| 03.02.2022 | Karolinska Development's portfolio company AnaCardio raises SEK 33 million to progress clinical development of a novel therapy for heart failure | STOCKHOLM, SWEDEN February 3, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed a fundraising of SEK 33 million comprised of a convertible loan. Karolinska Developmen... |
| 03.02.2022 | Karolinska Development's portfolio company AnaCardio raises SEK 33 million to progress clinical development of a novel therapy for heart failure | STOCKHOLM, SWEDEN February 3, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed a fundraising of SEK 33 million comprised of a convertible loan. Karolinska Developmen... |
| - | AnaCardio | “at a glance Heart failure is a leading cause of hospitalisation and death, and patients are currently underserved. AnaCardio was founded based on ground-breaking research from Karolinska Institutet Successfully performed a seed financing r... |
| - | AnaCardio | “AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.” |
